Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -2885.33% is 196563% below its 5-year average of -1.47%, near the high end of its 5-year range (-34689.20%–4043.34%).
63.46% above its 12-month average of -7896.13%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 1003.54%.
NET PROFIT MARGIN
-2885.33%
NET PROFIT MARGIN AVG TTM
-7896.13%
NET PROFIT MARGIN AVG 3Y
-412.91%
NET PROFIT MARGIN AVG 5Y
-1.47%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+63.46%
CURRENT VS 3Y AVG
-598.79%
CURRENT VS 5Y AVG
-196563.19%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-1109642.31%
vs the sector median at left
Surrozen, Inc.
Market Cap
$197.18M
Net Profit Margin
-2885.33%
TTM Avg
-7896.13%
3Y Avg
-412.91%
5Y Avg
-1.47%
Market Cap
$197.87M
Net Profit Margin
-26.61%
TTM Avg
-28.57%
3Y Avg
-51.55%
5Y Avg
-50.26%
Market Cap
$198.33M
Net Profit Margin
-10422.48%
TTM Avg
-2428.80%
3Y Avg
-1417.64%
5Y Avg
-1019.29%
Market Cap
$200.96M
Net Profit Margin
-850.13%
TTM Avg
-398.77%
3Y Avg
-257.91%
5Y Avg
-325.14%
Market Cap
$192.49M
Net Profit Margin
-36.80%
TTM Avg
-24.29%
3Y Avg
-59.84%
5Y Avg
-44.50%
Market Cap
$190.07M
Net Profit Margin
0.00%
TTM Avg
-122.98%
3Y Avg
-61.49%
5Y Avg
-40.99%
Market Cap
$189.11M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$205.80M
Net Profit Margin
-288.26%
TTM Avg
-266.69%
3Y Avg
-300.28%
5Y Avg
-1842.40%
Market Cap
$207.27M
Net Profit Margin
17.62%
TTM Avg
15.55%
3Y Avg
12.60%
5Y Avg
12.03%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Surrozen, Inc. (SRZN) | $197.18M | -2885.33% | -7896.13% | -412.91% | -1.47% |
| Exagen Inc. (XGN)vs › | $197.87M | -26.61% | -28.57% | -51.55% | -50.26% |
| Cartesian Therapeutics, Inc. (RNAC)vs › | $198.33M | -10422.48% | -2428.80% | -1417.64% | -1019.29% |
| Alector, Inc. (ALEC)vs › | $200.96M | -850.13% | -398.77% | -257.91% | -325.14% |
| RxSight, Inc. (RXST)vs › | $192.49M | -36.80% | -24.29% | -59.84% | -44.50% |
| Zentalis Pharmaceuticals, Inc. (ZNTL)vs › | $190.07M | 0.00% | -122.98% | -61.49% | -40.99% |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $189.11M | 0.00% | 0.00% | 0.00% | 0.00% |
| Whitehawk Therapeutics Inc (WHWK)vs › | $205.80M | -288.26% | -266.69% | -300.28% | -1842.40% |
| Pro-Dex, Inc. (PDEX)vs › | $207.27M | 17.62% | 15.55% | 12.60% | 12.03% |
| Electra Therapeutics Inc. (ETRA)vs › | $208.31M | N/A | N/A | N/A | N/A |
Operating Margin
-1210.6%
Net Profit Margin
-2885.3%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 1003.54% |
| 2026-03-31 | -2550.10% |
| 2025-12-31 | -34689.20% |
| 2025-09-30 | -7288.20% |
| 2025-06-30 | 4043.34% |
| 2025-03-31 | -2743.64% |
| 2024-12-31 | -4280.76% |
| 2024-09-30 | -14.34% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | -6.20% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |